Joe Burgess / Georgia Colkin / Annabel Atkins 077 6932 5254 Stifel Nicolaus Europe Limited, which also trades under the name Keefe, Bruyette & Woods ( KBW ), and which is authorised and regulated in the United Kingdom by the FCA, is acting as financial adviser to AFH and no-one else in connection with the matters described in this Announcement and will not be responsible to anyone other than AFH for providing the protections afforded to clients of KBW nor for providing advice in connection with the matters referred to herein. Neither KBW nor any of its affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of KBW in connection with this Announcement, any statement contained herein, the Acquisition or otherwise.
Capitalised terms used and not otherwise defined in this announcement have the meaning given to them in the Prospectus.
Important Information
The information contained in this announcement is given at the date of its publication (unless otherwise marked) and is subject to updating, revision and amendment from time to time.
This announcement does not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States. The New Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the Securities Act ) or under any securities laws of any state or other jurisdiction of the United States and may not be offered, sold, taken up, exercised, resold, renounced, transferred or delivered, directly or indirectly, within the United States except pursuant to an applicable exemption from or in a transaction not subject to the registration requirements of the Securities Act and in compliance
German
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.
Pivotal 6-month data readout for vamorolone in Duchenne muscular dystrophy (DMD) expected in the second quarter of 2021
Organization streamlined with a focus on cost savings and progressing vamorolone
Preliminary unaudited result for 2020: net sales CHF 15.0 million; net loss CHF 71.2 million; cash on hand as of December 31, 2020, CHF 12.4 million
Upsized financing from fund managed by Highbridge Capital Management, LLC (an existing investor in the Company), to satisfy liquidity needs through the next value-inflection point
Further strengthening of Santhera’s capital structure through a proposed convertible bond restructuring supported by its largest convertible bondholder representing approx. 32% of total bonds outstanding
Santhera Pharmaceuticals Holding AG: Santhera Announces Corporate Update and Proposal to Strengthen Capital Structure
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.
Pivotal 6-month data readout for vamorolone in Duchenne muscular dystrophy (DMD) expected in the second quarter of 2021
Organization streamlined with a focus on cost savings and progressing vamorolone
Preliminary unaudited result for 2020: net sales CHF 15.0 million; net loss CHF 71.2 million; cash on hand as of December 31, 2020, CHF 12.4 million
Upsized financing from fund managed by Highbridge Capital Management, LLC (an existing investor in the Company), to satisfy liquidity needs through the next value-inflection point
ReNeuron Group plc (the Company ) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that the following share option grants were made on 10 February 2021 under the Company s Long Term Incentive Plan (the Plan ), its US Incentive Stock Option Plan (the US Plan ) and its Non-Executive Share Option Scheme to directors and Persons Discharging Managerial Responsibilities (PDMRs) listed below. The Plan allows the Company to grant tax-advantaged share options under a Company Share Option Plan (the CSOP Plan ), as well as non-tax advantaged options. Where capacity exists for a director/PDMR to be issued share options under the CSOP Plan, these options are issued in parallel with non tax-advantaged options. The figures per individual below, where applicable and except where indicated, therefore comprise parallel grants of both CSOP Plan share options and non tax-advantaged share opti